Semaglutide yog glucagon-zoo li peptide-1 (GLP-1) receptor agonist qhia rau kev kho mob ntshav qab zib hom 2 thiab tswj qhov hnyav mus ntev. Nws ua haujlwm los ntawm kev siv cov tshuaj hauv plab hnyuv GLP-1 los ntawm cov txheej txheem uas suav nrog: stimulating insulin secretion kom txo cov ntshav qabzib; ncua lub plab khoob, ua kom satiety, thiab suppressing qab los pab kom poob phaus. Semaglutide feem ntau yog siv raws li kev txhaj tshuaj subcutaneous ib zaug ib lim tiam.
Khoom zoo:
1.Powerful hypoglycemic effect: txo qis HbA1c (txog 1.5%-2.0%).
2.Kev tswj qhov hnyav: Qhov nruab nrab qhov hnyav poob ntawm 10%-15% (cov ntaub ntawv soj ntsuam kuaj mob).
3.Cardiovascular cov txiaj ntsig: Txo qhov kev pheej hmoo ntawm cov kab mob plawv loj (xws li myocardial infarction thiab stroke) hauv cov neeg mob ntshav qab zib hom 2.
Khoom Qhia
Daim ntawv ntsuam xyuas
Cov lus teb rau cov neeg siv khoom
Kev xa khoom
